医药板块首选创新药；关注三大主线配置机会

Group 1 - The core viewpoint is that the banking sector is expected to see a performance turning point due to the accumulation of positive fundamental factors, supported by recent financial policies and stable interest margins [1] - The recent asymmetric interest rate cuts on deposits and loans have stabilized bank interest margins, providing a supportive environment for performance recovery [1] - The public fund allocation is expected to recover, accelerating the realization of bank dividend value in the medium to long term [1] Group 2 - The market is experiencing rapid rotation between large-cap and small-cap stocks, suggesting a need to focus on three main investment themes [2] - The first theme is to invest in assets with high safety margins, particularly dividend-paying sectors that offer stable returns amid increased external uncertainties [2] - The second theme emphasizes the technology sector, which remains a long-term investment focus, with short-term attention on undervalued sub-sectors [2] - The third theme highlights the consumer sector, which is expected to benefit from policy support and the ongoing importance of boosting domestic demand [2] Group 3 - The pharmaceutical sector is expected to prioritize innovative drugs, with a focus on consumption recovery as the industry progresses towards innovation by 2025 [3] - The aging population and unmet clinical needs are driving growth in the pharmaceutical industry, alongside improving innovation capabilities [3] - The pharmaceutical sector is anticipated to return to stable growth, particularly with the emergence of innovative drugs and the normalization of medical compliance [3]